异位性皮肤炎：KOL 见解

Atopic Dermatitis - KOL Insight

出版日期: 年间契约型资讯服务 | 出版商:

FirstWord Group | 英文

价格

简介目录

本报告调查了异位性皮肤炎治疗药物的最新趋势。根据一线 KOL 的见解，Lilly/Almirall 的 Ebglyss 预计将具有与 Dupixent 相当的功效和市场占有率。专家们也讨论了对 rocatinlimab（Kyowa Kirin/Amgen）的谨慎乐观态度，指出需要进一步进行疗效测试和副作用调查。此外，amlitelimab（Sanofi）已经显示出有趣的 IIb 期资料和有利的给药方案，儘管还需要更多资料。本报告目的是加深对塑造异位性皮肤炎治疗未来的新生物製剂和新兴疗法的了解。

除了完整报告外，授权使用者还可以透过附件存取以下 KOL 公告和特别报告：

本报告回答的关键问题：

Dupixent（Dupilumab；Sanofi/Regeneron）如何用于治疗异位性皮肤炎？进行哪些其他测试？未来将如何规定？
最近推出的产品中最有前景的作用机制和产品是什么？
哪些管道产品最有前途？它们将如何影响当前的市场参与者？
哪些临床试验可能会影响处方趋势？另外，该结果对未来异位性皮肤炎的治疗有何影响？
未来异位性皮肤炎的治疗现况将如何改变？

本报告调查的主要品牌

Dupixent (dupilumab)
Adbry/Adtralza (tralokinumab)
Ebglyss (lebrikizumab)
Olumiant (baricitinib)
Cibinqo (abrocitinib)

Rinvoq (upadacitinib)
nemolizumab
Velsipity (etrasimod)
rocatinlimab
amlitelimab

上市公司

AbbVie
Amgen
Lilly
Regeneron
Sanofi
Pfizer
Almirall S.A.

Leo Pharma
Incyte
Chugai
Galderma
Maruho
Kyowa Kirin

出于安全考虑，KOL 不认为 SYK/JAK 双重抑制可有效治疗异位性皮肤炎
- PD1 促效剂抗体被认为是高风险前景
- 大多数专家不认为 TYK2 抑制对异位性皮肤炎有效
- 双特异性抗体开发前景乐观
- 生物标记通常被认为是无关紧要的
- 减少给药频率在未来将变得越来越重要

附录

KOL（关键意见领袖）详细
- 美国的 KOL
- 欧洲的 KOL

简介目录

Explore the evolving landscape of atopic dermatitis treatment. Insights from leading KOLs highlight the promising potential of Lilly/Almirall's Ebglyss, which is expected to rival Dupixent in efficacy and market share. Experts also discuss the cautious optimism surrounding rocatinlimab (Kyowa Kirin/Amgen), noting the need for further efficacy validation and investigation into side effects. Additionally, amlitelimab (Sanofi) shows intriguing Phase IIb data with a favourable dosing schedule, though more data is required. Gain an understanding of the new biologics and emerging therapies shaping the future of atopic dermatitis treatment.

In addition to the full report, licensed users have access to the following KOL Bulletins and special reports via the attachments area.

Key questions answered:

How is Dupixent (dupilumab; Sanofi/Regeneron) used in the treatment of atopic dermatitis, what other trials are being conducted, and how will it be prescribed in the future?
Among recently launched products, which mechanisms of action and/or products are the most promising?
Which pipeline products are the most promising, and how will they impact current players in the market?
Which clinical trials have the potential to impact prescribing trends, and how will the results affect the future treatment of atopic dermatitis?
How will the treatment landscape for atopic dermatitis evolve in the future?

Key brands covered in this report:

Dupixent (dupilumab)
Adbry/Adtralza (tralokinumab)
Ebglyss (lebrikizumab)
Olumiant (baricitinib)
Cibinqo (abrocitinib)

Rinvoq (upadacitinib)
nemolizumab
Velsipity (etrasimod)
rocatinlimab
amlitelimab

Companies Listed:

AbbVie
Amgen
Lilly
Regeneron
Sanofi
Pfizer
Almirall S.A.

Leo Pharma
Incyte
Chugai
Galderma
Maruho
Kyowa Kirin

Executive summary

Future treatment paradigm for atopic dermatitis

Research objectives

Current treatment strategies

Dupixent (dupilumab; Sanofi/Regeneron)
- Key insights summary
Adbry/Adtralza (tralokinumab; LEO Pharma)
- Key insights summary
Ebglyss (lebrikizumab; Lilly/Almirall)
- Key insights summary
Olumiant (baricitinib; Lilly/Incyte)
- Key insights summary
Cibinqo (abrocitinib; Pfizer)
- Key insights summary
Rinvoq (upadacitinib; AbbVie)
- Key insights summary

Late-stage pipeline programmes

Nemolizumab (Galderma/Chugai/Maruho)
- Key insights summary
Velsipity (etrasimod; Pfizer)
- Key insights summary
Rocatinlimab (Kyowa Kirin/Amgen)
- Key insights summary
Amlitelimab (Sanofi)
- Key insights summary

Earlier-stage developments and other factors impacting treatment

KOLs are unconvinced that dual SYK/JAK inhibition will have a place in atopic dermatitis due to safety concerns
- PD1 agonist antibody is deemed to be a risky prospect
- Most experts don't think TYK2 inhibition will work as well in atopic dermatitis
- Optimism surrounds the development of bispecific antibodies
- Biomarkers are generally seen as irrelevant
- Less frequent dosing will become increasingly important in the future